Focus Surgery posts 1994 results

Article

Focus Surgery's net loss widened last year as the company geared up its sales and marketing effortfor Sonablate 200, which uses high-intensity focused ultrasoundto treat benign prostatic hyperplasia (SCAN 9/28/94). The Fremont,CA, firm reported total

Focus Surgery's net loss widened last year as the company geared up its sales and marketing effortfor Sonablate 200, which uses high-intensity focused ultrasoundto treat benign prostatic hyperplasia (SCAN 9/28/94). The Fremont,CA, firm reported total revenues for 1994 (end-December) of $1.6million, compared to total revenues of $1.9 million the year before.Focus Surgery's net loss grew to $7.7 million, compared to $6.6million in 1993. Sonablate 200 was granted German regulatory approvallast year and Focus has made six commercial sales worldwide. Focusis working on a premarket approval (PMA) application to the Foodand Drug Administration to sell the system in the U.S.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.